Skip to main content
Erschienen in: Journal of Assisted Reproduction and Genetics 9/2018

05.06.2018 | Fertility Preservation

Fertility preservation: ovarian response to freeze oocytes is not affected by different malignant diseases—an analysis of 992 stimulations

verfasst von: M . von Wolff, T. Bruckner, T. Strowitzki, A. Germeyer

Erschienen in: Journal of Assisted Reproduction and Genetics | Ausgabe 9/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To study if ovarian response is affected by the type of disease if fertility preservation is required.

Methods

A registry of the trinational fertility preservation network FertiPROTEKT including 992 patients aged 18–40 years undergoing ovarian stimulation and follicle aspiration for fertility preservation from 1/2007 until 3/2016 was analysed. The number of collected oocytes, days of stimulation, total gonadotropin dosage and gonadotropin dosage per day were evaluated.

Results

Total oocyte number was negatively correlated with increasing age (r = 0.237, p < 0.0001). Oocyte numbers were in women < 26 years 15.4 ± 8.8, 26–30 years 13.1 ± 8.5, 31–35 years 12.2 ± 7.7 and 36–40 years 9.9 ± 8.0. Age-adjusted oocyte numbers were not different in women with Hodgkin’s lymphoma (12.6 ± 8.8), non-Hodgkin’s lymphoma (12.4 ± 8.2), leukaemia (11.7 ± 8.2), sarcoma (11.8 ± 8.2), cerebral cancer (16.5 ± 8.1), gastrointestinal cancer (13.2 ± 8.1) gynaecological cancer (10.8 ± 8.2) and other types of malignancies (15.8 ± 8.1) apart from ovarian cancer with lower oocyte yield (7.3 ± 8.3, p < 0.001) compared to women with breast cancer (13.3 ± 8.8). The total gonadotropin dose used for stimulation was only elevated in Hodgkin’s and non-Hodgkin’s lymphoma compared to women with breast cancer (p < 0.05). Oocyte yield was lower in women with versus without ovarian cancer (p < 0.0001).

Conclusions

As ovarian response is not affected by the type of cancer, ovarian stimulation can be performed with the same oocyte yield in different malignant diseases. However, oocyte yield is reduced if ovarian surgery is required and in older women.
Literatur
1.
Zurück zum Zitat von Wolff M, Dittrich R, Liebenthron J, Nawroth F, Schüring AN, Bruckner T, et al. Fertility-preservation counselling and treatment for medical reasons: data from a multinational network of over 5000 women. Reprod BioMed Online. 2015;31:605–12.CrossRef von Wolff M, Dittrich R, Liebenthron J, Nawroth F, Schüring AN, Bruckner T, et al. Fertility-preservation counselling and treatment for medical reasons: data from a multinational network of over 5000 women. Reprod BioMed Online. 2015;31:605–12.CrossRef
2.
Zurück zum Zitat Bodri D, Guillén JJ, Galindo A, Mataró D, Pujol A, Coll O. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study. Fertil Steril. 2009;91:365–71.CrossRefPubMed Bodri D, Guillén JJ, Galindo A, Mataró D, Pujol A, Coll O. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study. Fertil Steril. 2009;91:365–71.CrossRefPubMed
3.
Zurück zum Zitat von Wolff M, Thaler CJ, Frambach T, Zeeb C, Lawrenz B, Popovici RM, et al. Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase. Fertil Steril. 2009;92:1360–5.CrossRef von Wolff M, Thaler CJ, Frambach T, Zeeb C, Lawrenz B, Popovici RM, et al. Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase. Fertil Steril. 2009;92:1360–5.CrossRef
4.
Zurück zum Zitat Cakmak H, Tran ND, Zamah AM, Cedars MI, Rosen MP. A novel “delayed start” protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders. Fertil Steril. 2014;101:1308–14.CrossRefPubMedPubMedCentral Cakmak H, Tran ND, Zamah AM, Cedars MI, Rosen MP. A novel “delayed start” protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders. Fertil Steril. 2014;101:1308–14.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat von Wolff M, Capp E, Jauckus J, Strowitzki T, Germeyer A, FertiPROTEKT study group. Timing of ovarian stimulation in patients prior to gonadotoxic therapy: an analysis of 684 stimulations. Eur J Obstet Gynecol Reprod Biol. 2016;199:146–9.CrossRef von Wolff M, Capp E, Jauckus J, Strowitzki T, Germeyer A, FertiPROTEKT study group. Timing of ovarian stimulation in patients prior to gonadotoxic therapy: an analysis of 684 stimulations. Eur J Obstet Gynecol Reprod Biol. 2016;199:146–9.CrossRef
6.
Zurück zum Zitat Kuang Y, Chen Q, Hong Q, Lyu Q, Ai A, Fu Y, et al. Double stimulations during the follicular and luteal phases of poor responders in IVF/ICSI programmes (Shanghai protocol). Reprod BioMed Online. 2014;29:684–91.CrossRefPubMed Kuang Y, Chen Q, Hong Q, Lyu Q, Ai A, Fu Y, et al. Double stimulations during the follicular and luteal phases of poor responders in IVF/ICSI programmes (Shanghai protocol). Reprod BioMed Online. 2014;29:684–91.CrossRefPubMed
7.
Zurück zum Zitat Huober-Zeeb C, Lawrenz B, Popovici RM, Strowitzki T, Germeyer A, Stute P, et al. Improving fertility preservation in cancer: ovarian tissue cryobanking followed by ovarian stimulation can be efficiently combined. Fertil Steril. 2011;95:342–4.CrossRefPubMed Huober-Zeeb C, Lawrenz B, Popovici RM, Strowitzki T, Germeyer A, Stute P, et al. Improving fertility preservation in cancer: ovarian tissue cryobanking followed by ovarian stimulation can be efficiently combined. Fertil Steril. 2011;95:342–4.CrossRefPubMed
8.
Zurück zum Zitat Kim J, Turan V, Oktay K. Long-term safety of letrozole and gonadotropin stimulation for fertility preservation in women with breast cancer. J Clin Endocrinol Metab. 2016;101:1364–71.CrossRefPubMedPubMedCentral Kim J, Turan V, Oktay K. Long-term safety of letrozole and gonadotropin stimulation for fertility preservation in women with breast cancer. J Clin Endocrinol Metab. 2016;101:1364–71.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Lawrenz B, Jauckus J, Kupka M, Strowitzki T, von Wolff M. Efficacy and safety of ovarian stimulation before chemotherapy in 205 cases. Fertil Steril. 2010;94:2871–3.CrossRefPubMed Lawrenz B, Jauckus J, Kupka M, Strowitzki T, von Wolff M. Efficacy and safety of ovarian stimulation before chemotherapy in 205 cases. Fertil Steril. 2010;94:2871–3.CrossRefPubMed
10.
Zurück zum Zitat Alvarez RM, Ramanathan P. Fertility preservation in female oncology patients: the influence of the type of cancer on ovarian stimulation response. Hum Reprod. 2016. Alvarez RM, Ramanathan P. Fertility preservation in female oncology patients: the influence of the type of cancer on ovarian stimulation response. Hum Reprod. 2016.
11.
Zurück zum Zitat Sonigo C, Comtet M, Duros S, Sifer C, Sermondade N, Grynberg M. Antral follicle responsiveness to FSH, assessed by the follicular output rate (FORT), is altered in Hodgkin’s lymphoma when compared with breast cancer candidates for fertility preservation. J Assist Reprod Genet. 2018;35:91–7.CrossRefPubMed Sonigo C, Comtet M, Duros S, Sifer C, Sermondade N, Grynberg M. Antral follicle responsiveness to FSH, assessed by the follicular output rate (FORT), is altered in Hodgkin’s lymphoma when compared with breast cancer candidates for fertility preservation. J Assist Reprod Genet. 2018;35:91–7.CrossRefPubMed
12.
Zurück zum Zitat Das M, Shehata F, Moria A, Holzer H, Son WY, Tulandi T. Ovarian reserve, response to gonadotropins, and oocyte maturity in women with malignancy. Fertil Steril. 2011;96:122–5.CrossRefPubMed Das M, Shehata F, Moria A, Holzer H, Son WY, Tulandi T. Ovarian reserve, response to gonadotropins, and oocyte maturity in women with malignancy. Fertil Steril. 2011;96:122–5.CrossRefPubMed
13.
Zurück zum Zitat Friedler S, Koc O, Gidoni Y, Raziel A, Ron-El R. Ovarian response to stimulation for fertility preservation in women with malignant disease: a systematic review and meta-analysis. Fertil Steril. 2012;97:125–33.CrossRefPubMed Friedler S, Koc O, Gidoni Y, Raziel A, Ron-El R. Ovarian response to stimulation for fertility preservation in women with malignant disease: a systematic review and meta-analysis. Fertil Steril. 2012;97:125–33.CrossRefPubMed
14.
Zurück zum Zitat Almog B, Azem F, Gordon D, Pauzner D, Amit A, Barkan G, et al. Effects of cancer on ovarian response in controlled ovarian stimulation for fertility preservation. Fertil Steril. 2012;98:957–60.CrossRefPubMed Almog B, Azem F, Gordon D, Pauzner D, Amit A, Barkan G, et al. Effects of cancer on ovarian response in controlled ovarian stimulation for fertility preservation. Fertil Steril. 2012;98:957–60.CrossRefPubMed
15.
Zurück zum Zitat Lawrenz B, Fehm T, von Wolff M, Soekler M, Huebner S, Henes J, et al. Reduced pretreatment ovarian reserve in premenopausal female patients with Hodgkin lymphoma or non-Hodgkin-lymphoma—evaluation by using antimüllerian hormone and retrieved oocytes. Fertil Steril. 2012;98:141–4.CrossRefPubMed Lawrenz B, Fehm T, von Wolff M, Soekler M, Huebner S, Henes J, et al. Reduced pretreatment ovarian reserve in premenopausal female patients with Hodgkin lymphoma or non-Hodgkin-lymphoma—evaluation by using antimüllerian hormone and retrieved oocytes. Fertil Steril. 2012;98:141–4.CrossRefPubMed
16.
Zurück zum Zitat Garcia-Velasco JA, Domingo J, Cobo A, Martínez M, Carmona L, Pellicer A. Five years’ experience using oocyte vitrification to preserve fertility for medical and nonmedical indications. Fertil Steril. 2013;99:1994–9.CrossRefPubMed Garcia-Velasco JA, Domingo J, Cobo A, Martínez M, Carmona L, Pellicer A. Five years’ experience using oocyte vitrification to preserve fertility for medical and nonmedical indications. Fertil Steril. 2013;99:1994–9.CrossRefPubMed
17.
Zurück zum Zitat Lekovich J, Lobel ALS, Stewart JD, Pereira N, Kligman I, Rosenwaks Z. Female patients with lymphoma demonstrate diminished ovarian reserve even before initiation of chemotherapy when compared with healthy controls and patients with other malignancies. J Assist Reprod Genet. 2016;33:657–62.CrossRefPubMedPubMedCentral Lekovich J, Lobel ALS, Stewart JD, Pereira N, Kligman I, Rosenwaks Z. Female patients with lymphoma demonstrate diminished ovarian reserve even before initiation of chemotherapy when compared with healthy controls and patients with other malignancies. J Assist Reprod Genet. 2016;33:657–62.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Quinn MM, Cakmak H, Letourneau JM, Cedars MI, Rosen MP. Response to ovarian stimulation is not impacted by a breast cancer diagnosis. Hum Reprod. 2017;32:568–74.PubMed Quinn MM, Cakmak H, Letourneau JM, Cedars MI, Rosen MP. Response to ovarian stimulation is not impacted by a breast cancer diagnosis. Hum Reprod. 2017;32:568–74.PubMed
19.
Zurück zum Zitat Drakopoulos P, Blockeel C, Stoop D, Camus M, de Vos M, Tournaye H, et al. Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos? Hum Reprod. 2016;31:370–6.PubMed Drakopoulos P, Blockeel C, Stoop D, Camus M, de Vos M, Tournaye H, et al. Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos? Hum Reprod. 2016;31:370–6.PubMed
20.
Zurück zum Zitat Caponecchia L, Cimino G, Sacchetto R, Fiori C, Sebastianelli A, Salacone P, et al. Do malignant diseases affect semen quality? Sperm parameters of men with cancers. Andrologia. 2016;48:333–40.CrossRefPubMed Caponecchia L, Cimino G, Sacchetto R, Fiori C, Sebastianelli A, Salacone P, et al. Do malignant diseases affect semen quality? Sperm parameters of men with cancers. Andrologia. 2016;48:333–40.CrossRefPubMed
21.
Zurück zum Zitat Johnson LN, Dillon KE, Sammel MD, Efymow BL, Mainigi MA, Dokras A, et al. Response to ovarian stimulation in patients facing gonadotoxic therapy. Reprod BioMed Online. 2013;26:337–44.CrossRefPubMedPubMedCentral Johnson LN, Dillon KE, Sammel MD, Efymow BL, Mainigi MA, Dokras A, et al. Response to ovarian stimulation in patients facing gonadotoxic therapy. Reprod BioMed Online. 2013;26:337–44.CrossRefPubMedPubMedCentral
Metadaten
Titel
Fertility preservation: ovarian response to freeze oocytes is not affected by different malignant diseases—an analysis of 992 stimulations
verfasst von
M . von Wolff
T. Bruckner
T. Strowitzki
A. Germeyer
Publikationsdatum
05.06.2018
Verlag
Springer US
Erschienen in
Journal of Assisted Reproduction and Genetics / Ausgabe 9/2018
Print ISSN: 1058-0468
Elektronische ISSN: 1573-7330
DOI
https://doi.org/10.1007/s10815-018-1227-0

Weitere Artikel der Ausgabe 9/2018

Journal of Assisted Reproduction and Genetics 9/2018 Zur Ausgabe

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.